| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Abstract
China has the second largest animal health and nutrition market in the world
-- it was worth $1.5 billion in 2004 and is forecast to grow to $2.4 billion
by 2010. Most of the world's leading companies have invested in the market.
However, reliable information on this market has been hard to find ... until
now.
This new Animal Pharm report is written by industry specialists Beijing Orient
Agribusiness Consultant, and is essential reading for all senior managers who
are already competing in the Chinese animal health and nutrition sector, or
who are investigating the huge potential of this market.
This report features:
- A detailed market analysis, quantifying market sizes, reviewing the key
sectors, and identifying those with the best opportunities for foreign
investors
- An analysis of the business environment of the animal health and nutrition
sector, including industry structure, regulation, foreign investment,
distribution and international trade
- A review of the market drivers that will determine the growth of the
animal health and nutrition market over the next decade
- An investigation of the Chinese commercial livestock industry, discussing
how government policy, China's entry into the WTO, changing consumer
preferences and agricultural intensification will influence the development of
the industry
- Profiles of 30 leading domestic and international companies in the sector
- Background to China, putting the animal health and nutrition industry in
context
Answers all your questions including:
- Is China creating "national champions" in the animal health industry that
can compete with the established multinationals, and what threat will they
represent?
- What is the Chinese government's livestock policy, and what effect will
this have on the industry over the next decade?
- Which multinational animal health and nutrition companies have invested in
factories in China -- and are they making any money?
- Which markets are price-sensitive and dominated by generics, and which
allow companies to develop price premiums for branded products?
|
